Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.
Hosted on MSN
AlphaFold opens new doors in drug development—how
AlphaFold, a transformative AI-driven tool developed by DeepMind, has revolutionized the field of structural biology by accurately predicting protein structures. This breakthrough holds significant ...
Pharmaceutical Technology on MSN
Parkinson’s research reaches pivotal stage, but barriers remain
Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.
Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...
The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...
DUBLIN--(BUSINESS WIRE)--The "Molecular Switches As Therapeutic Targets, Drug Development, Drug Delivery Mechanism & Application By Indications Insight 2025" report has been added to ...
The most familiar artificial intelligence (AI) applications include text generation, facial recognition, and autonomous driving. But there are other AI applications that deserve their share of ...
Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.
Neuroinflammation drives the progression of neurodegenerative disorders like Alzheimer's, Parkinson's, and multiple sclerosis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results